|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1996-5-22
|
|
pubmed:abstractText |
Modern induction chemotherapy produce 60% to 80% complete remission in adults with newly diagnosed acute myelogenous leukemia (AML). A major challenge is to eradicate subclinical disease in remission and prevent leukemic relapse. Intensive post-remission chemotherapy was proved of comparable disease-free survival as BMT.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0578-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
305-11
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8605644-Adolescent,
pubmed-meshheading:8605644-Adult,
pubmed-meshheading:8605644-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8605644-Cytarabine,
pubmed-meshheading:8605644-Etoposide,
pubmed-meshheading:8605644-Female,
pubmed-meshheading:8605644-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:8605644-Humans,
pubmed-meshheading:8605644-Leukemia, Myeloid, Acute,
pubmed-meshheading:8605644-Male,
pubmed-meshheading:8605644-Middle Aged,
pubmed-meshheading:8605644-Mitoxantrone,
pubmed-meshheading:8605644-Neutropenia,
pubmed-meshheading:8605644-Remission Induction
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
|
|
pubmed:affiliation |
Department of Medicine, Veterans General Hospital-Taipei, Taiwan, R.O.C.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
